BRANY Announces New Agreement to Boost Clinical Trial Participation

Share Article

BRANY selected as U.S. prime site for Quintiles.

BRANY (Biomedical Research Alliance of New York) has announced it has been designated a Quintiles Prime Site. The designation will advance BRANY’s participation in clinical trials by providing improved access to new industry-sponsored clinical trials.

BRANY joins other select organizations that have received the same designation from Quintiles across the USA, Europe, Africa and Asia. BRANY is committed to excellence in the conduct of clinical research, and the company supports Quintiles’ vision to bring people and knowledge together for a healthier world. BRANY’s network of highly qualified and experienced researchers and track record in working with community and academic study sites will accelerate the development of new therapies.

“BRANY is committed to excellence in clinical research and improving patient care , says Kimberly Irvine, Executive Vice President of Operations at BRANY. “This alliance will provide our leading investigators and hospitals with significant opportunities to access industry-sponsored clinical trials. We are excited to be working with Quintiles to bring new clinical trials to our sites and patients.”

BRANY’s Smart Start 60 increases efficiencies and sustainability among their community and academic study sites to expedite clinical research timelines. These efficiencies translate to real-life benefits as clinical trials are concluded on or ahead of schedule to advance treatments for unmet medical needs in a cost-effective way that does not jeopardize the quality standards of the of research.

“We have been working with BRANY for 14 years and are continuously impressed with the calibre of their investigator network and the quality of their research,” said Lindy Jones, Senior Vice President, Integrated Site Services, Quintiles. “BRANY consistently sets and meets aggressive start-up timelines. They are able to conduct studies in both the hospital and community setting broadening opportunities for patients to participate in studies. We welcome BRANY as the newest Prime Site and look forward to continued success together.”

About BRANY
BRANY (Biomedical Research Alliance of New York) is a national organization providing clinical trial support services to sponsors and investigators involved in research in a wide variety of therapeutic areas, medical devices, biologic and diagnostic trials. Staffed by multi-disciplinary experts, BRANY is an expedited, AAHRPP-accredited "end-to-end solution" for clinical trials including study procurement, clinical study budget/contracting and IRB review. BRANY’s Smart Start 60 provides an efficient process enabling clinical trial study start in 60 days while maintaining a commitment to the highest level of human subject protection. BRANY’s Smart Start 60 offers hospitals and investigators a unique continuum of clinical trial support services, which results in study start up in 60 days compared to typical hospital start up times of for IRB review/clinical trial contracting of 3-6months. With a robust network of site affiliates, BRANY is able to offer its partners a turnkey solution for expedited site identification and study startup. For more information, please visit http://www.brany.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Emily Avila
BRANY
4156480544
Email >
Follow us on
Visit website

Media